Alexander Spira, MD, PhD, Discusses Approval of Agents to Treated NSCLC With Exon 20 Insertion Mutations

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about future indications of mobocertinib.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about how an FDA approval of mobocertinib [TAK-788] could positivity impact patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations. 


Right now, there are no future trials looking at [mobocertinib in patients previously treated with EGFR inhibitor] specifically. In the United States, we have an approved drug amivantamab [Rybrevant] for [EGFR] exon 20 insertion–mutant non-small cell lung cancer, which is a very different approach. It’s a monoclonal antibody versus mobocertinib, and the others described, which are small molecule TKIs. What we’ll all be interested to see is if you give mobocertinib first and they respond to amivantamab, or if you give amivantimab first, will they respond to mobocertinib. So [providers] think that’s where the field is going right now. In terms of TKIs, it’s likely that we will see mobocertinib approved in the short term—or at least, we hope we will in the United States—giving us that armamentarium. Whether the other TKIs play in at this point remains to be seen.

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Related Content